Amgen

KANJINTI

Manufacturer:

Amgen

Kanjinti HCPCS:

Q5117

HCPCS Code Descriptor:

Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg

Category:

Q Code

Kanjinti NDCs:

55513-0132-01, 55513-0141-01, 55513-0164-01

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Kanjinti:

KANJINTI is an Oncology Biosimilar drug manufactured by Amgen and administered via the Intravenous route of administration. The Q Code: Q5117 is aligned to the drug KANJINTI.

Kanjinti (trastuzumab) is a HER2 inhibitor that is used to treat certain types of stomach and breast cancer. Kanjinti can be used by itself or in combination with other cancer medications. It is manufactured by Amgen USA and is biosimilar to the medication Herceptin (J9356). Kanjinti has been aligned to the Q Code Q5117 since October 2019.

ACCESS PRICING AND MORE BY REGISTERING

Q5117 Added Date:

October 1, 2019

Q5117 Effective Date:

October 1, 2019

Q5117 Termination Date:

HCPCS Active

Kanjinti billing and coding information can be found through Amgen at the link below:
Kanjinti patient assistance information can be found through Amgen SupportPlus at the URL: https://www.amgensupportplus.com/patient/kanjinti
KANJINTI prescribing information can be found at the link below:
Information regarding KANJINTI’s side effects can be found at MedlinePlus